JP2004500380A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004500380A5 JP2004500380A5 JP2001559460A JP2001559460A JP2004500380A5 JP 2004500380 A5 JP2004500380 A5 JP 2004500380A5 JP 2001559460 A JP2001559460 A JP 2001559460A JP 2001559460 A JP2001559460 A JP 2001559460A JP 2004500380 A5 JP2004500380 A5 JP 2004500380A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cell proliferation
- rheumatoid arthritis
- treating rheumatoid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18263500P | 2000-02-15 | 2000-02-15 | |
| PCT/US2001/004095 WO2001060363A1 (en) | 2000-02-15 | 2001-02-08 | A method for synthesizing leflunomide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004500380A JP2004500380A (ja) | 2004-01-08 |
| JP2004500380A5 true JP2004500380A5 (enExample) | 2006-01-05 |
Family
ID=22669359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001559460A Pending JP2004500380A (ja) | 2000-02-15 | 2001-02-08 | レフルノミドの合成方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US6723855B2 (enExample) |
| EP (1) | EP1257270B1 (enExample) |
| JP (1) | JP2004500380A (enExample) |
| KR (1) | KR20020072312A (enExample) |
| AT (1) | ATE292966T1 (enExample) |
| AU (1) | AU2001234943A1 (enExample) |
| CA (1) | CA2400290A1 (enExample) |
| CZ (1) | CZ20023024A3 (enExample) |
| DE (1) | DE60110043T2 (enExample) |
| ES (1) | ES2237553T3 (enExample) |
| HR (1) | HRP20020671A2 (enExample) |
| HU (1) | HUP0301865A3 (enExample) |
| IL (1) | IL151196A0 (enExample) |
| PL (1) | PL366088A1 (enExample) |
| SK (1) | SK12992002A3 (enExample) |
| WO (1) | WO2001060363A1 (enExample) |
| YU (1) | YU61602A (enExample) |
| ZA (1) | ZA200206494B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0987256B1 (de) * | 1997-08-08 | 2001-10-17 | Aventis Pharma Deutschland GmbH | Kristallform von N-(4-Trifluormethylphenyl)-5-methylisoxazol-4-carbonsäureamid |
| YU45102A (sh) * | 1999-12-16 | 2006-01-16 | Teva Pharmaceutical Industries Ltd. | Novi kristalni oblik leflunomida i novi postupci za njegovo dobijanje |
| GB0123571D0 (en) * | 2001-04-05 | 2001-11-21 | Aventis Pharm Prod Inc | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
| US20030139606A1 (en) * | 2001-11-09 | 2003-07-24 | Ray Anup Kumar | Process for preparing 5-methylisoxazole-4-carboxylic- (4'-trifluoromethyl)-anilide |
| US7875616B2 (en) * | 2003-05-27 | 2011-01-25 | Haegerkvist Robert Per | Use of tyrosine kinase inhibitor to treat diabetes |
| WO2005041940A1 (en) * | 2003-10-30 | 2005-05-12 | Lupin Ltd. | Stable formulations of ace inhibitors and methods for preparation thereof |
| US20060024376A1 (en) * | 2004-07-30 | 2006-02-02 | The University Of Chicago | Methods and compositions for reducing toxicity associated with leflunomide treatment |
| DE102005017592A1 (de) * | 2005-04-16 | 2006-10-19 | Lindner, Jürgen, Dr. med. | Darreichungsformen und Kombinationspräparate von Pyrimidinbiosyntheseinhibitoren zur Erzielung zusätzlicher Wirkungen auf das Immunsystem |
| WO2007086076A2 (en) * | 2006-01-24 | 2007-08-02 | Unichem Laboratories Limited | An improved process for preparation of leflunomide |
| CN101817797B (zh) * | 2009-02-26 | 2013-04-10 | 江苏亚邦爱普森药业有限公司 | 高纯度3-甲基-n-[4-(三氟甲基)苯基]-4-异噁唑甲酰胺的合成方法 |
| CR20170078A (es) | 2009-09-18 | 2017-05-22 | Sanofi Sa | Formulaciones en compromido de la (4-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibutil-2-enoico con estabilidad mejorada |
| CN102002009B (zh) * | 2010-10-18 | 2012-11-07 | 齐鲁制药有限公司 | 一种5-甲基异恶唑-4-甲酰氯的制备方法 |
| CA2989394C (en) * | 2015-06-17 | 2023-08-01 | Biocon Limited | A novel process for the preparation of teriflunomide |
| JOP20190207A1 (ar) * | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2854439A1 (de) | 1978-12-16 | 1980-07-03 | Hoechst Ag | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
| GB8619432D0 (en) | 1986-08-08 | 1986-09-17 | Lilly Industries Ltd | Pharmaceutical compounds |
| CA2083179C (en) * | 1990-05-18 | 2001-10-23 | Robert Ryder Bartlett | Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use |
| EP0607775B1 (de) | 1993-01-08 | 1998-12-09 | Hoechst Aktiengesellschaft | Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta |
| US5610173A (en) * | 1994-01-07 | 1997-03-11 | Sugen, Inc. | Formulations for lipophilic compounds |
| EP0987256B1 (de) * | 1997-08-08 | 2001-10-17 | Aventis Pharma Deutschland GmbH | Kristallform von N-(4-Trifluormethylphenyl)-5-methylisoxazol-4-carbonsäureamid |
| DE19908527C2 (de) * | 1999-02-26 | 2001-08-30 | Aventis Pharma Gmbh | Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid |
| YU45102A (sh) * | 1999-12-16 | 2006-01-16 | Teva Pharmaceutical Industries Ltd. | Novi kristalni oblik leflunomida i novi postupci za njegovo dobijanje |
-
2001
- 2001-02-08 WO PCT/US2001/004095 patent/WO2001060363A1/en not_active Ceased
- 2001-02-08 YU YU61602A patent/YU61602A/sh unknown
- 2001-02-08 AU AU2001234943A patent/AU2001234943A1/en not_active Abandoned
- 2001-02-08 AT AT01907127T patent/ATE292966T1/de not_active IP Right Cessation
- 2001-02-08 HR HRP20020671 patent/HRP20020671A2/hr not_active Application Discontinuation
- 2001-02-08 KR KR1020027010595A patent/KR20020072312A/ko not_active Ceased
- 2001-02-08 US US09/779,928 patent/US6723855B2/en not_active Expired - Fee Related
- 2001-02-08 CA CA002400290A patent/CA2400290A1/en not_active Abandoned
- 2001-02-08 IL IL15119601A patent/IL151196A0/xx unknown
- 2001-02-08 PL PL01366088A patent/PL366088A1/xx not_active Application Discontinuation
- 2001-02-08 CZ CZ20023024A patent/CZ20023024A3/cs unknown
- 2001-02-08 DE DE60110043T patent/DE60110043T2/de not_active Expired - Fee Related
- 2001-02-08 SK SK1299-2002A patent/SK12992002A3/sk unknown
- 2001-02-08 HU HU0301865A patent/HUP0301865A3/hu unknown
- 2001-02-08 EP EP01907127A patent/EP1257270B1/en not_active Expired - Lifetime
- 2001-02-08 JP JP2001559460A patent/JP2004500380A/ja active Pending
- 2001-02-08 ES ES01907127T patent/ES2237553T3/es not_active Expired - Lifetime
-
2002
- 2002-08-14 ZA ZA200206494A patent/ZA200206494B/en unknown
-
2003
- 2003-12-10 US US10/730,949 patent/US20040127532A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002533216A5 (enExample) | ||
| AU2003299791A1 (en) | Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity | |
| JP2004500380A5 (enExample) | ||
| HUP0401293A3 (en) | Novel dihydropteridinones, method for producing the same and the use thereof as medicaments | |
| JP2006501215A5 (enExample) | ||
| WO2004006834A3 (en) | Leflunomide analogs for treating rheumatoid arthritis | |
| MXPA03009645A (es) | Proceso para preparar oxazolidinonas. | |
| IL162316A0 (en) | Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition t | |
| AU2003265589A8 (en) | Process for the preparation of 1,1,1,2,2-pentafluoroethane | |
| MXPA03010019A (es) | COMPOSICIoN PARA TRATAR EL ESTREnIMIENTO INDUCIDO POR FaRMACOS CON 15-CETO-PROSTAGLANDINAS. | |
| EP1724283A3 (en) | Corticotropin releasing factor receptor 2 agonists | |
| WO2002030357A3 (en) | Compounds and methods for modulating ccr4 function | |
| ZA200206808B (en) | Endoparasiticidal gel composition. | |
| JP2004518665A5 (enExample) | ||
| PL359847A1 (pl) | Kompozycja w postaci cząstek, zawierająca eletryptan, o kontrolowanym uwalnianiu według profilu sigmoidalnego | |
| ZA200309514B (en) | Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives. | |
| TW200512207A (en) | Substituted 3-(2, 5-disubstituted)pyridyl-4-aryl pyrroles for treating inflammatory diseases | |
| ZA200500526B (en) | Prodrug, medicinal utilization thereof and process for producing the same | |
| AU2003210812A1 (en) | Stable pharmaceutical composition useful for treating gastrointestinal disorders | |
| MXPA02004860A (es) | 3-(4,5-dihdroisoxazol-5-il) benzoilpirazoles. | |
| EP1565448A4 (en) | PROCESS FOR THE PREPARATION OF 10H-DIBENZOçB, F] ç1,4] THIAZEPIN-11-ON | |
| JP2003284553A5 (enExample) | ||
| EG23417A (en) | Process for the preparation 7 a-methylsteroids. | |
| AU2003223992A1 (en) | Solid stabilizer composition, the production and the use thereof | |
| MXPA03005965A (es) | Composicion farmaceutica que contiene citalopram. |